A year ago, the impact of COVID-19 vaccines was at the forefront of everybody’s minds. Our base case was that they would be effective, become widely available and allow the economy to recover, which proved largely accurate. However, COVID-19 very much remains with us, as the emergence of the new Omicron variant has reminded us.
Om dit artikel te lezen heeft u een abonnement op Investment Officer nodig. Heeft u nog geen abonnement, klik op "Abonneren" voor de verschillende abonnementsregelingen.
